Human epidermal growth factor (EGF) is a polypeptide that binds to the receptor EGFR and initiates a chain of reactions to activate gene pathways involved in cell growth and proliferation. Recombinant human epidermal growth factor (rhEGF) is expressed in prokaryotic and eukaryotic biological systems such as bacteria, plants, and others. Recombinant human EGF can be effectively used for the treatment of acute and chronic wounds such as Stevens-Johnson syndrome, diabetic foot ulcers, scalds, bedsores, and others. rhEGF also finds its use in the cosmetics industry for improving the texture of the skin, for reducing scar formation, and for reducing hyperpigmentation, etc. In addition, rhEGF can be used to prepare synthetic culture medium, which is used in the field of bioengineering for producing prosthetic organs. Moreover, recombinant human EGF can be used for the treatment of eye damage by promoting the epidermal cell growth and repair process in the eye.
Global Recombinant Human EGF Market - Impact of the Coronavirus (COVID-19) Pandemic
Coronavirus (COVID-19) outbreak was first reported on December 31, 2019, in Wuhan, China. The World Health Organization declared COVID-19, as pandemic on March 11, 2020.
According to the Coronavirus (COVID-19) Weekly Epidemiological Update by the World Health Organization, over 180,492,131 cases and 3,916,771 deaths due to coronavirus disease (COVID-19) were reported till June 27, 2021, across the globe.
Impact of COVID-19 on Demand and Supply of Recombinant Human EGF
The COVID-19 pandemic and lockdown in various countries across the globe have impacted the financial status of businesses across all sectors. The biotechnology sector is one such sector that has been majorly impacted by the pandemic.
The COVID-19 pandemic has impacted the entire supply chain of the biotechnology industry mainly due to strict lockdown in several regions. COVID-19 pandemic has resulted in a decrease in non-emergency operations/procedures such as cataract surgery, eye laser surgery, and others. According to the National Centre for Biotechnology Information (NCBI), in 2020, the total number of outpatient department treatment (OPD) visits decreased by 96.6% at a tertiary-care ophthalmology institute in Tamil Nadu, India. This was due to the national lockdown, which led to the restriction of movement that further resulted in decreased OPD visits as compared to 2019.
Thus, the impact of the coronavirus (COVID-19) pandemic is expected to limit the growth of the global recombinant human EGF market during the forecast period, owing to the decrease in ophthalmology procedures during the pandemic as recombinant human EGF is used in treatment of eye damages.
Figure 1: Global Recombinant Human EGF Market Share, (%), Analysis, By Application, 2021
Growing research in the field of recombinant technology is the major factor that is expected to drive the market growth over the forecast period.
The rising cases of chronic wounds, corneal damage, acute wounds, and others are expected to drive growth of recombinant human EGF market over the forecast period. For instance, a report published by Ecronicon in May 2020, stated that the prevalence of foot ulcers was 4-10% across the globe and on an average of 17.2 million hospital visits per year were concerned with wound treatments.
Moreover, the increasing number of research and development activities for exploring various uses of recombinant human EGF is expected to aid in the growth of the market over the forecast period. For instance, according to a research study published by NCBI (National Center for Biotechnology Information) in July 2020, Ocean University of China, and Luoyang Normal University, China developed a new delivery system using nanoparticles for the delivery of recombinant human EGF to the wound site. This novel system helps in improving bioavailability of EGF at the wound site and also help in maintaining its sustained release.
|Base Year:||2020||Market Size in 2021:||US$ 10,251.1 Mn|
|Historical Data for:||2017 to 2020||Forecast Period:||2021 to 2028|
|Forecast Period 2021 to 2028 CAGR:||9.3%||2028 Value Projection:||US$ 19,103.4 Mn|
Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc., and BioVision, Inc.
|Restraints & Challenges:||
Global Recombinant Human EGF Market – Restraints
However, growth of the recombinant human EGF market may be hampered, owing to the high cost and disparity in efficiency of various recombinant human EGF. According to a research study published in MDPI (Multidisciplinary Digital Publishing Institute) in April 2019, potential uses of EGF have not been completely translated into commercially available products due to the high production cost of recombinant human epidermal growth factor. Moreover, according to a review article by Analytical & Pharmaceutical Research Journal in 2017, few isoforms of recombinant human EGF exhibit low levels of bioavailability and stability. Also, the same source reveals that use of some structurally different recombinant human EGF for the treatment of diabetic ulcer wounds showed different efficacies and inconsistent results.
Global Recombinant Human EGF Market – Regional Analysis
On the basis of region, the global recombinant human EGF market is segmented into North America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to hold dominant position in the global recombinant human EGF market over the forecast period, owing to rising incidence of diabetes. For instance, according to National Diabetes Statistics Report- 2020 by Centers of Disease Control and Prevention, around 34.2 million people in the U.S. have diabetes while 34.5% of the U.S population are prediabetic. This is expected to boost the market growth of recombinant human EGF market as the rhEGFs are widely used for the treatment of diabetic foot ulcers.
Figure 2: Global Recombinant Human EGF Market Value (US$ 3,987.7 Mn), by Region, 2021
Global Recombinant Human EGF Market – Competitive Landscape
Major players operating in the global recombinant human EGF market include Thermo Fisher Scientific, FUJIFILM Irvine Scientific, Inc., ScienCell Research Laboratories, R&D Systems, Abcam PLC, Cell Sciences, Inc., Eurofins DiscoverX, PeproTech, Inc., RayBiotech, Inc., Prospec-Tany TechnoGene Ltd., Miltenyi Biotec, Tonbo Biosciences, BioLegend, Inc., EnQuire BioReagents, STEMCELL Technologies Inc., Cell Guidance Systems Ltd., Creative BioMart, Sino Biological Inc. and BioVision, Inc.
Recombinant Human EGF (Epidermal Growth Factor) is a peptide that binds to the membrane receptor called EGF receptor in humans to promote cell proliferation and cell differentiation. EGF acts by initiating number of cell signaling cascade pathways such as activating genes for cell proliferation, cell differentiation, protein synthesis, and improving efficiency of DNA topoisomerase. Traditionally, EGF was isolated from animal urine but with recent advances in biotechnology, the production and extraction of recombinant EGF have become possible in a lab setting. Recombinant EGF can be produced using various biological systems such as Escherichia coli, tobacco, rice, yeast, and others. EGF can be used for several applications in the field of medicine, research, cell culture, cosmetology, and others. EGF exhibits medically important properties such as initiation of growth and division in cells that can be exploited for clinical application of wound healing as well as for the treatment of ulcers. For instance, according to an article published by the American Institute of Physics in June 2020, high levels of recombinant human EGF (rhEGF) were obtained by co-expression of human EGF (hEGF) in Escherichia coli with Bacillus cereus phospholipase C. This rhEGF can then be used for the treatment of diabetic foot ulcers along with other wound treatments.
Market players are conducting clinical trials for analyzing the potential uses of human EGF in healthcare sector, this could contribute to the growth of the market over the forecast period. For instance, a clinical trial study was initiated in July 2017 by Hallym University Kangnam Sacred Heart Hospital, Korea, for determining the effectiveness of recombinant human EGF ointment in healing lesions caused by laser treatment for solar lentigines. The study was completed in December 2018 and the results were published by PubMed in February 2021. Results showed that the use of recombinant human EGF ointment was safe and efficient for healing lesions.
Market players are involved in acquisitions of other companies in order to enhance distribution. For instance, in 2018, FUJIFILM, a Japanese multinational conglomerate, acquired Irvine Scientific Sales Company, Inc., a cell media specialist, to expand its range of cell culture media products including recombinant human EGF. This is expected to drive the growth of the recombinant human EGF market.
Key features of the study:
“*” marked represents similar segmentation in other categories in the respective section.